[Effectiveness and tolerance of the C3 convertase inhibitor, N-acetyl-aspartyl-magnesium glutamate in perennial rhinitis. Results of a double-blind, placebo-controlled study].
N-Acetyl-aspartyl magnesium glutamate (Rhinaaxia, NAAGA) is a new antiallergic substance for topical use. The compound covers a bilateral way of action. There is inhibition of the mast cell-degranulation and blocking of the C3-convertase, subsequently followed by a blocked cleavage of the fragments C3a and C5a, respectively. 20 patients suffering from perennial allergic rhinitis were treated according to a randomized double blind placebo-controlled study design. Apart from a nominal documentation of subjective complaints the degree of nasal obstruction was objectively rated via rhinomanometria. The nasal flow rate improved significantly in patients treated with NAAGA and subjective complaints decreased markedly. NAAGA showed to be well tolerated although 6 of 10 patients observed transient "nasal burning".
Harnest
U
U
Praxis für Pneumologie und Allergologie, München.
Kiehn
R
R
Sieger
C
C
Weibel
M A
MA
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D004151:Dipeptides / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008365:Manometry; D008875:Middle Aged; D009297:Nasal Mucosa / Q000503:physiopathology; D011897:Random Allocation; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*
D004151:Dipeptides; C027172:isospaglumic acid
Wirksamkeit und Verträglichkeit des C3-Konvertasehemmers N-Acetyl-Aspartyl-Magnesiumglutamat bei perennialer Rhinitis. Ergebnis einer doppelblinden, Plazebo-kontrollierten Untersuchung.